TY  - GEN
AU  - Lee,Kyung-Hun
AU  - Im,Seock-Ah
AU  - Oh,Do-Youn
AU  - Lee,Se-Hoon
AU  - Chie,Eui Kyu
AU  - Han,Wonshik
AU  - Kim,Dong-Wan
AU  - Kim,Tae-You
AU  - Park,In Ae
AU  - Noh,Dong-Young
AU  - Heo,Dae Seog
AU  - Ha,Sung Whan
AU  - Bang,Yung-Jue
TI  - Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
SN  - 1471-2407
PY  - 2007///0511
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - Breast Neoplasms
KW  - chemistry
KW  - Chemotherapy, Adjuvant
KW  - Cohort Studies
KW  - Combined Modality Therapy
KW  - Cyclophosphamide
KW  - administration & dosage
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Drug Administration Schedule
KW  - Female
KW  - Follow-Up Studies
KW  - Gene Expression Regulation, Neoplastic
KW  - Genes, bcl-2
KW  - Humans
KW  - Ki-67 Antigen
KW  - analysis
KW  - Lymph Node Excision
KW  - Mastectomy, Modified Radical
KW  - Mastectomy, Segmental
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Paclitaxel
KW  - Prognosis
KW  - Proto-Oncogene Proteins c-bcl-2
KW  - Radiotherapy, Adjuvant
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Survival Analysis
KW  - Tamoxifen
KW  - Tumor Suppressor Protein p53
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/1471-2407-7-63
ER  -